Back to top

CleanCap® Cas9 mRNA (5moU) - (L-7206)

CleanCap® CRISPR Associated Protein 9 mRNA (5-methoxyuridine)
In stock
Product SKU Unit Size Price Qty
L-7206-100 100 µg
L-7206-1000 1 mg
L-7206-5 5 x 1 mg



Cas9 mRNA expresses a version of the Streptococcus pyogenes SF370 Cas9 protein (CRISPR Associated Protein 9). Cas9 functions as part of the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) genome editing system. In the CRISPR system, an RNA guide sequence targets the site of interest and the Cas9 protein is employed to perform double stranded DNA cleavage.

Cas9 mRNA encodes the Cas9 protein with an N and C terminal nuclear localization signal (NLS). The incorporation of two NLS signals within the mRNA increases the frequency of delivery to the nucleus, thus increasing the rate of DNA cleavage. Additionally, a C terminal HA epitope tag aids detection, isolation, and purification of the Cas9 protein.

This mRNA is capped using CleanCap, TriLink's proprietary co-transciptional capping method, which results in the naturally occuring Cap 1 structure with high capping efficiency. It is polyadenylated, substituted with a modified uridine and optimized for mammalian systems. It mimics a fully processed mature mRNA.

Product details
Catalog No L-7206
Purity Passes Agarose Gel Mobility
Length 4521 nucleotides
Base Composition Fully substituted with 5-Methoxy-U
Concentration 1.0 mg/mL
Buffer 1 mM Sodium Citrate pH 6.4
Conversion Factor 40 µg/OD260
Recommended Storage At or below -40°C
Application CRISPR, Immunotherapeutics, Recombinases
Cap AG Start, Cap 1, CleanCap
Other Name(s) CleanCap® CRISPR Associated Protein 9 mRNA (5-methoxyuridine)
Technical documents

L-7206 Safety Data Sheet

L-7206 Product Insert

CleanCap Cas9 ORF Sequence

Products faqs

They all contain an optimal 5′ Cap 1 found in higher eukaryotes for their functionality and stability. They also contain a synthetic 5′ UTR with a strong Kozak sequence for efficient translation and a 3′ UTR derived from mouse alpha-globin. Their key differences lie in the type of CleanCap® analog used and the sequence compositions, which may affect their protein expression and immunogenicity.


CleanCap® mRNAs

CleanCap® mRNAs (5moU)

CleanCap® M6 mRNAs (N1MePsU)

Expression system




5′ cap

Cap 1

Cap 1

Cap 1

Cap analog

CleanCap® AG

CleanCap® AG

CleanCap® M6

5′ and 3′ UTRs




Poly(A) tail

120 nt

120 nt

120 nt

Sequence composition

Unmodified uridines

Uridines substituted with 5-methoxyuridines

Uridines substituted with N1-methylpseudouridines

Protein expression









It is TriLink’s proprietary in vitro transcription method that produces high-quality, high-yield mRNAs from a broad range of sequences. It has been optimized to minimize dsRNA and improve in vivo protein expression from the resulting mRNAs. Please see here for more information.

Our catalog mRNAs are intended for research use and manufactured with procedures in place to minimize endotoxin exposure. However, they are manufactured outside of a cleanroom and thus are not released with an endotoxin specification.  If you need mRNA released with an endotoxin specification or a higher grade of material, please contact [email protected].

We recommend storing the mRNAs at -400 C to -800 C. To minimize freeze-thaw cycles, aliquot the sample into single-use quantities on the first usage. If kept under these conditions, our catalog mRNAs have been shown to maintain stability for at least 2 years.

The sequence reported is just the ORF, start codon to stop codon, for our catalog mRNAs. It does not include the proprietary 5′ UTR, 3′ UTR, or the 120-nt poly-A tail. For full mRNA length and the length of the ORF please see the corresponding product insert.

Our catalog mRNAs are purified through DNase treatment to remove DNA templates, diafiltration to remove salts and small molecules, and oligo dT capture to remove impurities and retain species with poly(A) tails. 

We do not carry Cy5-labeled mRNAs as catalog products. You may order them as a custom mRNA by completing this request form.

Our CleanCap® Cas9 mRNA, CleanCap® Cas9 mRNAs (5moU), and CleanCap® Cas9 mRNA (N1MePsU) contain an HA tag, 5′ TACCCCTACGACGTGCCCGACTACGCC 3′. 

We use the dot blot test, which is a qualitative test to determine the relative amount of dsRNA present in a sample. Generally, this test is performed to assess dsRNA levels in mRNAs before and after RP-HPLC purification.

We minimize the dsRNA level in our ready-to-use mRNAs by incorporating stringent processes that consist of:

  • In vitro transcription using our proprietary CleanScript™ method or the CleanCap® M6 protocol
  • Multiple post-IVT purification steps

We also assess dsRNA level in the sample by dot blot as part of quality analysis.

We look for a single main band running to approximately the correct length to pass the gel result.  Some factors such as modified NTPs can make a sample run slightly lower than the expected size.  Sometimes, sequence-related factors such as highly repetitive or UTP-rich regions (especially when modified UTP is used) can result in additional bands.  We take account of all these factors to confirm that the mRNA was manufactured appropriately and the band is sequence specific before passing the results.

The fragment analyzer reports the percent of smear with a chromatogram. The smear analysis corresponds to the full-length integrity of an mRNA sample.

We start by cleaving the 5′ end of the mRNAs, then use LCMS to determine the mass of capped and uncapped species by the following formula:

We use 40 as the extinction coefficient for our mRNAs. Assigning a sequence-specific extinction coefficient for mRNA can be problematic due to its dependence on length and sequence composition.  Factors like final buffer and temperature can also impact results.  Thus, it is standard to use 40 for all mRNA species and not to calculate a coefficient for each sequence as you would with an oligonucleotide.

Certificate of analysis

CoA search tool

Intellectual property

CRISPR/Cas9 License For research use only. Provided with a limited use license under licenses with The Broad Institute and ERS Genomics Ltd.

CleanCap capping technology For Research Use Only. Not for use in humans. Not for use in diagnostic or therapeutic purposes. For additional licensing restrictions, please see the license agreement at Patents and patent pending, see

Products are for research use only, not for use in diagnostic or therapeutic procedures or for use in humans. Products are not for resale without express written permission from TriLink No license under any patent or other intellectual property right of TriLink or its licensors is granted or implied by the purchase unless otherwise provided in writing.

TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser's sole responsibility.

  1. Guo, Q.; Mintier, G.; Ma-Edmonds, M.; Storton, D.; Wang, X.; Xiao, X.; Kienzle, B.; Zhao, D.; Feder, John N. . 'Cold shock' increases the frequency of homology directed repair gene editing in induced pluripotent stem cells.
  2. Ghanem, Louis R.; Kromer, Andrew; Silverman, Ian M.; Ji, Xinjun; Gazzara, Matthew; Nguyen, Nhu; Aguilar, Gabrielle; Martinelli, Massimo; Barash, Yoseph; Liebhaber, Stephen A. . Poly(C)-Binding Protein Pcbp2 Enables Differentiation of Definitive Erythropoiesis by Directing Functional Splicing of the Runx1 Transcript.
  3. Gainetdinov, Ildar; Colpan, Cansu; Arif, Amena; Cecchini, Katharine; Zamore, Phillip D. . A Single Mechanism of Biogenesis, Initiated and Directed by PIWI Proteins, Explains piRNA Production in Most Animals.
  4. Hall, Bradford; Cho, Andrew; Limaye, Advait; Cho, Kyoungin; Khillan, Jaspal; Kulkarni, Ashok B. . Genome Editing in Mice Using CRISPR/Cas9 Technology.
  5. Shen, B;Tasdogan, A;Ubellacker, JM;Zhang, J;Nosyreva, ED;Du, L;Murphy, MM;Hu, S;Yi, Y;Kara, N;Liu, X;Guela, S;Jia, Y;Ramesh, V;Embree, C;Mitchell, EC;Zhao, YC;Ju, LA;Hu, Z;Crane, GM;Zhao, Z;Syeda, R;Morrison, SJ; . A mechanosensitive peri-arteriolar niche for osteogenesis and lymphopoiesis
  6. Xu, H;Wu, L;Nguyen, HH;Mesa, KR;Raghavan, V;Episkopou, V;Littman, DR; . Arkadia-SKI/SnoN signaling differentially regulates TGF-?-induced iTreg and Th17 cell differentiation
  7. Rosenblum, D;Gutkin, A;Kedmi, R;Ramishetti, S;Veiga, N;Jacobi, AM;Schubert, MS;Friedmann-Morvinski, D;Cohen, ZR;Behlke, MA;Lieberman, J;Peer, D; . CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy
  8. Guan, Y;Leu, NA;Ma, J;Chm . SKP1 drives the prophase I to metaphase I transition during male meiosis
  9. Baxley, RM;Leung, W;Schmit, MM;Matson, JP;Yin, L;Oram, MK;Wang, L;Taylor, J;Hedberg, J;Rogers, CB;Harvey, AJ;Basu, D;Taylor, JC;Pagnamenta, AT;Dreau, H;Craft, J;Ormondroyd, E;Watkins, H;Hendrickson, EA;Mace, EM;Orange, JS;Aihara, H;Stewart, GS;Blair, E;Cook, JG;Bielinsky, AK; . Bi-allelic MCM10 variants associated with immune dysfunction and cardiomyopathy cause telomere shortening
  10. Fulgenzi, G;Hong, Z;Tomassoni-Ardori, F;Barella, LF;Becker, J;Barrick, C;Swing, D;Yanpallewar, S;Croix, BS;Wess, J;Gavrilova, O;Tessarollo, L; . Novel metabolic role for BDNF in pancreatic ?-cell insulin secretion
  11. Zhang, J;Cohen, A;Shen, B;Du, L;Tasdogan, A;Zhao, Z;Shane, EJ;Morrison, SJ; . The effect of parathyroid hormone on osteogenesis is mediated partly by osteolectin
  12. Katoku-Kikyo, N;Paatela, E;Houtz, DL;Lee, B;Munson, D;Wang, X;Hussein, M;Bhatia, J;Lim, S;Yuan, C;Asakura, Y;Asakura, A;Kikyo, N; . Per1/Per2-Igf2 axis-mediated circadian regulation of myogenic differentiation
  13. Yang, F;Lan, Y;Pandey, RR;Homolka, D;Berger, SL;Pillai, RS;Bartolomei, MS;Wang, PJ; . TEX15 associates with MILI and silences transposable elements in male germ cells
  14. Yamulla, RJ;Nalubola, S;Flesken-Nikitin, A;Nikitin, AY;Schimenti, JC; . Most Commonly Mutated Genes in High-Grade Serous Ovarian Carcinoma Are Nonessential for Ovarian Surface Epithelial Stem Cell Transformation
  15. Abbasi, S;Uchida, S;Toh, K;Tockary, T;Dirisala, A;Hayashi, K;Fukushima, S;Kataoka, K; . Co-encapsulation of Cas9 mRNA and guide RNA in polyplex micelles enables genome editing in mouse brain
  16. Roelofs, PA;Goh, CY;Chua, BH;Jarvis, MC;Stewart, TA;McCann, JL;McDougle, RM;Carpenter, MA;Martens, JW;Span, PN;Kappei, D;Harris, RS; . Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B
  17. Scott, T;Soemardy, C;Morris, K; . Development of a facile approach for generating chemically-modified CRISPR/Cas9 RNA
  18. Delgado, C;Bu, L;Zhang, J;Fang-Yu, L;Sall, J;Liang, FX;Furley, AJ;Fishman, GI; . Neural cell adhesion molecule (NCAM-1) is required for ventricular conduction system development
  19. Ji, X;Jha, A;Humenik, J;Ghanem, LR;Andrew, K;Duncan-Lewis, C;Traxler, E;Weiss, MJ;Barash, Y;Liebhaber, SA; . RNA-binding proteins PCBP1 and PCBP2 are critical determinants of murine erythropoiesis
  20. Xu, Y;Liu, R;Leu, NA;Zhang, L;Ibragmova, I;Schultz, DC;Wang, PJ; . A cell-based high-content screen identifies isocotoin as a small molecule inhibitor of the meiosis-specific MEIOB-SPATA22 complex
  21. . The testis-specific transcription factor TCFL5 responds to A-MYB to elaborate the male meiotic program in placental mammals
  22. Tabdanov, E;Rodr . Engineering T cells to enhance 3D migration through structurally and mechanically complex tumor microenvironments
  23. Aldossary, AM; . Correction of the ?F508 Mutation in the CFTR Gene by CRISPR/Cas9 System
  24. Nambiar, TS; . Leveraging DNA Damage Response Pathways to Enhance the Precision of CRISPR-Mediated Genome Editing
  25. Rodriguez Merced, N; . Capturing Cell Dynamics in Live Pancreatic Adenocarcinoma
  26. Herskovitz, J;Hasan, M;Patel, M;Blomberg, WR;Cohen, JD;Machhi, J;Shahjin, F;Mosley, RL;McMillan, J;Kevadiya, BD;Gendelman, HE; . CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination
  27. Kenjo, E;Hozumi, H;Makita, Y;Iwabuchi, KA;Fujimoto, N;Matsumoto, S;Kimura, M;Amano, Y;Ifuku, M;Naoe, Y;Inukai, N;Hotta, A; . Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice
  28. Fekete, S;Yang, H;Wyndham, K;Lauber, M; . Salt gradient and ion-pair mediated anion exchange of intact messenger ribonucleic acids
  29. Gainetdinov, I;Colpan, C;Cecchini, K;Arif, A;Jouravleva, K;Albosta, P;Vega-Badillo, J;Lee, Y; . Terminal modification, sequence, length, and PIWI-protein identity determine piRNA stability
Show more